What is Microbix Biosystems Inc. (MBXBF)?

Microbix Biosystems Inc. (MBXBF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of MBXBF?

The current price of MBXBF is $0.22. Prices are updated in real time on Stocks360.

What is MBXBF's price-to-earnings (PE) ratio?

MBXBF's trailing twelve-month PE ratio is -8.22, based on current price and earnings per share data available on Stocks360.

What is MBXBF's market capitalization?

MBXBF's market capitalization is $30,133,180.00, placing it in the small-cap tier.

Microbix Biosystems Inc. (MBXBF)

Stock analysis · OTC · Healthcare · Biotechnology

$0.22

Market Cap

$30.13M

PE (TTM)

-8.22

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.57

Day Range

$0.22 – $0.22

52-wk Range

$0.15 – $0.23

Avg Volume

N/A

Volume

2.50K

Microbix Biosystems Inc. (MBXBF) is a publicly traded company in the Healthcare sector. Latest price: $0.22. Market cap $30.13M. Trailing PE -8.22. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 8 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $0.18 2026-10-29 · $0.22 (+20.95%)

Earnings

Most Recent

Dec 19, 2023

EPS $0.01 vs est. $-0.00

Beat by $0.01

Next Earnings

Dec 17, 2026

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Microbix Biosystems Inc.

Microbix Biosystems Inc. is a life sciences enterprise that invents and markets unique biological and technological innovations designed to improve human health and well-being. Operating across North America, Europe, and other international markets, the company primarily produces essential biological reagents for the diagnostics industry. This includes antigens for immunoassays and its proprietary Quality Assessment and Proficiency (QAP) products. These QAPs are crucial for supporting clinical laboratory proficiency testing, aiding in assay development and validation, and streamlining lab workflows. Furthermore, Microbix leverages its biological knowledge and infrastructure to create other specialized products, such as its DxTM (viral transport medium) for stabilizing patient samples for laboratory analysis, and Kinlytic Urokinase, a biologic drug for treating blood clots. Its QAP offerings are sold to laboratory accreditation organizations, diagnostic firms, and clinical laboratories via a network of regional distributors. Founded in 1988, Microbix Biosystems Inc. is headquartered in Mississauga, Canada.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-8.22×
P/S (TTM)	2.58×
P/B	1.61×
PEG	0.06×
P/FCF (TTM)	-10.22×
EV / EBITDA	-17.08×
EV / Sales	2.55×
Earnings Yield	-12.53%
Free Cash Flow Yield	-9.79%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$39.28M
Revenue (TTM)	$15.40M
Net Income (TTM)	-$4.98M
Free Cash Flow (TTM)	-$3.15M
Net Debt	-$440.07K
Working Capital	$18.09M
Gross Margin	45.90%
Operating Margin	-27.69%
Net Margin	-31.72%
Return on Equity	-18.83%
Return on Invested Capital	-13.51%